The comparison of dispersed compositions of drug aerosols generated from an aqueous suspension, aqueous and glycolic solutions Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004
A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Estimation of efficiency of new combined preparation built-in-liposomes budesonide compared with water budesonide suspension Source: Eur Respir J 2004; 24: Suppl. 48, 83s Year: 2004
Stability of a new formulation of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
A preliminary assessment of the stability of 5-CF containing liposomes following aerosolisation with TouchSprayÔ technology and a commercial jet nebuliser Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003
Epoprostenol with expanded stability has the same pharmacokinetic and hemodynamic profiles as epoprostenol in healthy subjects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Effect of nanoparticles on the respiratory epithelium in vitro : role of chemical composition and particle size Source: Eur Respir J 2007; 30: Suppl. 51, 476s Year: 2007
In vitro fine particle characteristics of budesonide containing MDI and DPI products Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
Improved effect in vivo of a lung surfactant extract by taking time-dependent aqueous swelling behaviour into account Source: Eur Respir J 2001; 18: Suppl. 33, 7s Year: 2001
Effect of different ventilation techniques on surfactant stability and metabolism Source: Research Seminar 2009 - The rationale and use of surfactant and continuous positive airway pressure (CPAP) in extremely low gestational age neonates (ELGANs) Year: 2009
Inhaled liposomal iloprost shows high drug encapsulation, extended release profile and potentials of improving patient compliance Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Analysis of solubilization time of human bronchial mucus in isotonic saline solution through photoacoustic technique Source: Eur Respir J 2005; 26: Suppl. 49, 485s Year: 2005
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Aerosolization of nanoparticle suspensions in ethanol using Mystic™ drug delivery technology Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Characterization of the activity of the different oligomeric forms of pulmonary human surfactant protein SP-D Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019
Effects of human activities and air purification on concentrations of airborne microorganisms and particles in a bronchoscopy room. Source: International Congress 2017 – Smoking, apnoea, infection, allergens and other factors Year: 2017
Effects of Cys85 on biochemical properties and biological function of human SP-A variants Source: Annual Congress 2007 - Bronchiolitis - genetics and immunity Year: 2007
Validation of monodisperse corticosteroid aerosols for in-vivo delivery Source: Annual Congress 2008 - Investigation, inspiration, ventilation, dedication: the essence of physiological measurement Year: 2008
Late Breaking Abstract - Capture efficiency of mechanically nebulised synthetic nanoparticles, liposomes, SARS-CoV-2 virus-like particles, and infectious pseudotyped virions is influenced by particle surface charge Source: Virtual Congress 2021 – Back to infection basics Year: 2021